- Home
- GYRE
as 09-02-2025 4:00pm EST
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 897.1M | IPO Year: | N/A |
| Target Price: | $18.00 | AVG Volume (30 days): | 86.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.11 - $19.00 | Next Earning Date: | 08-11-2025 |
| Revenue: | $102,189,000 | Revenue Growth: | -8.42% |
| Revenue Growth (this year): | 21.04% | Revenue Growth (next year): | 89.64% |
Latest Gyre Therapeutics Inc. News
GYRE Breaking Stock News: Dive into GYRE Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 months ago
Public companies account for 71% of Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ownership, while individual investors account for 19%
GlobeNewswire
3 months ago
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
GlobeNewswire
3 months ago
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire
3 months ago
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
GlobeNewswire
3 months ago
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
GlobeNewswire
3 months ago
Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
Simply Wall St.
4 months ago
Gyre Therapeutics First Quarter 2025 Earnings: EPS: US$0.031 (vs US$0.09 in 1Q 2024)
GlobeNewswire
4 months ago
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Compare GYRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GYRE Gyre Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.